ID: ALA1091426

Max Phase: Preclinical

Molecular Formula: C16H11BrN2O3

Molecular Weight: 359.18

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  COc1ccc(C2=N/C(=C\c3cccnc3)C(=O)O2)cc1Br

Standard InChI:  InChI=1S/C16H11BrN2O3/c1-21-14-5-4-11(8-12(14)17)15-19-13(16(20)22-15)7-10-3-2-6-18-9-10/h2-9H,1H3/b13-7-

Standard InChI Key:  BTISEUNLGQBPKF-QPEQYQDCSA-N

Associated Targets(Human)

Death-associated protein kinase 3 2108 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 359.18Molecular Weight (Monoisotopic): 357.9953AlogP: 3.20#Rotatable Bonds: 3
Polar Surface Area: 60.78Molecular Species: NEUTRALHBA: 5HBD: 0
#RO5 Violations: 0HBA (Lipinski): 5HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 4.68CX LogP: 3.23CX LogD: 3.23
Aromatic Rings: 2Heavy Atoms: 22QED Weighted: 0.62Np Likeness Score: -1.16

References

1. Okamoto M, Takayama K, Shimizu T, Muroya A, Furuya T..  (2010)  Structure-activity relationship of novel DAPK inhibitors identified by structure-based virtual screening.,  18  (7): [PMID:20206532] [10.1016/j.bmc.2010.02.018]

Source